Searched for
SARABJIT K NANGRA
Sikka exit costs Narayana Murthy Rs 1,000 cr, others Rs 29K cr! Time to panic?The news of Sikka's resignation wiped off Rs 30,000 crore off Infosys’ investor wealth.- Protectionist US - A major challenge for Indian IT servicesWhile acquiring skills is important to be able to deliver digital work, in the immediate term, local hiring could be a bigger concern, part...
- Why Infosys needs to figure out the best way to utilise $5billion it is sitting onShareholders want to know how quickly Sikka will shift to digital model he’s driving, from the worker arbitrage system dominant when the fo...
- Five reasons why Ratan Tata picked N Chandrasekaran for the top jobSpearheading TCS since he took over as CEO and MD in 2009, Chandra has shown he can take tough business decisions and challenge the status ...
- Why TCS CEO N Chandrasekaran is the favourite for the post of Tata Sons ChairmanA five-man panel that includes Ratan Tata, Mistry's predecessor and the interim chairman, has been tasked with finding a new chairman.
- $1 billion bet: GSK Pharma a short-term sell, long-term buy, say expertsThe stock is at rich valuations despite low sales and profit growth. The open offer by its parent firm is attractively priced, say experts.
- Good monsoon leads rural growth story with a bright spot for India Inc, investorsExperts say investors should bet on companies that have the ability to raise prices and trade at reasonable valuations.
- High power costs to drag margins of pharma firmsMajority of Indian pharmaceutical companies fear pressure on profit margins by at least 300-400 basis points as Andhra Pradesh, which accou...
- Union Budget 2011: Export duty hike on iron not to impact steel pricingThe Budget propsal is seen more to preserve a critical raw material for Indian steel companies that have announced expansion plans which wo...
- Now, USV looks for generic gains in a tough US marketIn spite of challenging market conditions, more and more Indian pharma companies are entering the US generic drugs market.
- Windfall for cos eyeing US oncology marketWith anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
Load More
